Drug Trial Radar · NCT05217628
An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.
Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
166
Actual
Start
Jan 11, 2022
Primary completion
Feb 2, 2027
Study completion Apr 24, 2027
Sponsor
- Lead sponsor
- Noema Pharma AGIndustry
- Sponsor type
- Industry
- First posted
- Feb 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Trigeminal neuralgia (TN), also called "tic douloureux", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice. This study is designed to evaluate the efficacy and safety of 1.5mg - 3.5mg basimglurant in adults with TN.
Conditions
- Trigeminal Neuralgia
Interventions
BasimglurantDrug
Period 1: Basimglurant 1.5 to 3.5 mg QD titrated on individual tolerability. Period 2: Patients randomized to receive either double blind Basimglurant at the tolerated dose from Period 1 or Placebo. OLE: Open label Basimglurant at the dose tolerated from Period 2, patients previously assigned placebo in period to be titrated to the Period 1.
PlaceboOther
Participant randomized to receive matching placebo once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Period 1: Incidence and severity of adverse events, laboratory, vital signs and cardiovascular events.Time frame: 8 weeks
- Period 2: Time to Loss of Efficacy or pain recurrence defined as the confirmed increase in the number of weekly paroxysms or re-emergence of continuous pain and/or the need for rescue medication.Time frame: 12 weeks
- Open Label Extension: Incidence and severity of adverse events, laboratory, vital signs and cardiovascular events.Time frame: 52 weeks
Locations
34 sites in 8 countries. Site status is shown where the registry gives one.
Kaizen Brain Center (Site #: 1001)
La Jolla, California
L & A Morales Healthcare INC (Site#: 1011)
Miami, Florida
University of South Florida (Site #: 1002)
Tampa, Florida
Vista Clinical Research,LLC (Site#: 1010)
Newnan, Georgia
Beth Israel Deaconess Medical Center (Site #: 1004)
Boston, Massachusetts
Altea Research - Nevada - ClinEdge - PPDS (Site #1006)
Las Vegas, Nevada
Columbia University - Irving Medical Center (Site #: 1008)
New York, New York
University of Cincinnati (Site #: 1007)
Cincinnati, Ohio
Danish Headache Center (Site #: 1201)
Glostrup Municipality, Denmark
Universitätsklinikum Bonn (Site #: 1707)
Bonn, Germany
Azienda Ospedaliera Universitaria Careggi (Site #: 1806)
Florence, Italy
Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta (Site #: 1804)
Milan, Italy
Università Campus Bio Medico Di Roma (Site #: 1805)
Rome, Lazio, Italy
IRCCS San Raffaele Pisana (Site #: 1801)
Rome, Lazio, Italy
La Sapienza-Università di Roma-Policlinico Umberto I (Site #: 1802)
Rome, Lazio, Italy
Niepubliczny Zaklad Opieki Zdrowotnej (NZOZ) Zespo (Site #: 2602)
Dąbrowa Górnicza, Poland
Centrum Medyczne Linden (Site #: 2605)
Krakow, Poland
FutureMeds - Lodzi - PPDS (Site #: 2606)
Lodz, Poland
Prywatny Gabinet Lekarski U. Chyrchel-Paszkiewicz (Site #: 2604)
Lublin, Poland
MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak (Site #: 2601)
Wroclaw, Poland
Hospital Universitario Fundacion Jimenez Diaz (Site #: 1903)
Madrid, Madrid, Spain
Hospital Universitario La Paz - PPDS (Site #: 1907)
Madrid, Madrid, Spain
Hospital Universitario Virgen del Rocio - PPDS (Site #: 1904)
Seville, Sevilla, Spain
Hospital Clinico Universitario de Valencia (Site #: 1906)
Valencia, Valencia, Spain
Afyon Kocatepe University Faculty of Medicine (Site #: 9005)
Afyonkarahisar, Turkey (Türkiye)
Uludag University Faculty of Medicine Hospital (Site #: 9001)
Bursa, Turkey (Türkiye)
Istanbul University Istanbul Medical Faculty Hospital (Site #: 9003)
Istanbul, Turkey (Türkiye)
Bagcilar Medipol Mega University Hospital (Site #: 9002)
Istanbul, Turkey (Türkiye)
Kocaeli University Faculty of Medicine Hospital (Site #: 9004)
Kocaeli, Turkey (Türkiye)
Mersin University Faculty of Medicine Hospital (Site #: 9007)
Mersin, Turkey (Türkiye)
Duzce University Health Application and Research Center (9008)
Düzce, Düzce, Turkey (Türkiye)
Selcuk University Medical Faculty (Site #: 9006)
Selçuklu, Konya, Turkey (Türkiye)
St. Thomas' Hospital (Site #: 2504)
London, London, United Kingdom
St Pancras Clinical Research (Site #: 2503)
London, Middlesex, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.